HC Wainwright set a $30.00 price target on Omeros (NASDAQ:OMER) in a research report released on Monday, February 19th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
OMER has been the topic of several other reports. Maxim Group set a $24.00 target price on Omeros and gave the stock a buy rating in a report on Wednesday, January 3rd. Cowen lowered Omeros from an outperform rating to a market perform rating in a research report on Thursday, November 2nd. Zacks Investment Research lowered Omeros from a hold rating to a sell rating in a report on Thursday, November 9th. ValuEngine upgraded Omeros from a sell rating to a hold rating in a report on Friday, February 2nd. Finally, Wedbush reissued an outperform rating and issued a $47.00 price objective on shares of Omeros in a research note on Tuesday, November 28th. Two analysts have rated the stock with a sell rating, four have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Omeros has a consensus rating of Hold and an average price target of $28.75.
Omeros (OMER) traded up $0.11 during mid-day trading on Monday, reaching $11.06. The company had a trading volume of 643,219 shares, compared to its average volume of 1,360,000. The company has a market cap of $530.92, a price-to-earnings ratio of -9.37 and a beta of 3.57. Omeros has a one year low of $8.36 and a one year high of $27.09. The company has a current ratio of 4.12, a quick ratio of 4.10 and a debt-to-equity ratio of -29.93.
Omeros (NASDAQ:OMER) last released its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.03). The company had revenue of $13.76 million during the quarter, compared to the consensus estimate of $21.94 million. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.45) EPS. equities research analysts predict that Omeros will post -0.76 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Capital Wealth Advisors acquired a new stake in shares of Omeros during the 4th quarter worth approximately $415,000. MetLife Investment Advisors LLC purchased a new position in shares of Omeros during the 4th quarter worth approximately $417,000. Millennium Management LLC purchased a new position in shares of Omeros during the 4th quarter worth approximately $925,000. Teachers Advisors LLC boosted its position in Omeros by 7.1% in the 4th quarter. Teachers Advisors LLC now owns 80,820 shares of the biopharmaceutical company’s stock valued at $1,570,000 after buying an additional 5,355 shares during the period. Finally, Ellington Management Group LLC purchased a new position in Omeros in the 4th quarter valued at approximately $301,000. Institutional investors and hedge funds own 48.56% of the company’s stock.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.